Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Max S. Topp, MD, Zachary F. Zimmerman, MD PhD, Paul Cannell, MD, Herve Dombret, MD, Anthony S. Stein, MD, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong, PhD, Andre Schuh, MD FRCPC

Blood (2017) 130 (Supplement 1): 2571.

https://doi.org/10.1182/blood.V130.Suppl_1.2571.2571

Published: 2017

Journal Articles

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Alessandro Rambaldi, MD Prof, Françoise Rigal-Huguet, MD, Pavel Zak, Paul Cannell, MD, Kun Nie, PhD, Zachary F. Zimmerman, MD PhD, Max S. Topp, MD

Blood (2017) 130 (Supplement 1): 2552.

https://doi.org/10.1182/blood.V130.Suppl_1.2552.2552

Published: 2017

Journal Articles

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Max S Topp, MD, Zachary Zimmerman, MD PhD, Paul Cannell, MD, Hervé Dombret, MD PhD, Johan Maertens, MD PhD, Andre C. Schuh, MD FRCPC, Janet Franklin, MD MPH, Kun Nie, PhD, Ze Cong

Blood (2016) 128 (22): 222.

https://doi.org/10.1182/blood.V128.22.222.222

Published: 2016

Journal Articles

Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Michael D. Tarantino, MD, James B. Bussel, MD, Amy Geddis, MD, Michael F. Guerrera, MD, Alan K. Ikeda, MD, Kun Nie, PhD, Melissa Eisen, MD

Blood (2013) 122 (21): 3530.

https://doi.org/10.1182/blood.V122.21.3530.3530

Published: 2013

Journal Articles

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

David J Kuter, MD, DPhil, James B Bussel, MD, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Troy Guthrie, MD, Jeffrey Wasser, MD, Lara Gehl, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 402.

https://doi.org/10.1182/blood.V112.11.402.402

Published: 2008

Journal Articles

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

James George, MD, James B Bussel, MD, Roger M Lyons, MD, Vinod Pullarkat, MD, Robert Redner, MD, Deirdra Terrell, PhD, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 4707.

https://doi.org/10.1182/blood.V112.11.4707.4707

Published: 2008

NARROW

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

Email alerts

ASH Publications

American Society of Hematology

Health-Related Quality of Life in Adults Treated with Blinatumomab Using the Acute Lymphoblastic Leukemia Symptom Scale

Maintenance Therapy with Blinatumomab in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL): Overall Survival in Adults Enrolled in a Phase 3 Open-Label Trial

Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relaspsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER)

Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only